Evidence map›Paper›PMID 42158839›Full record

ArticleLung Cancer (Auckland, N.Z.)2026

HER2-ADC and HER2-TKI Overcomes HER2 Amplification as an Acquired Resistance to Zongertinib - A Case Report.

Misako Nagasaka, Zhaohui L Arter, Cathleen J Park, Akshat Sarkari, Sai-Hong Ignatius Ou

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Lung Cancer (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Misako NagasakaDepartment of Medicine, University of California Irvine School of Medicine, Orange, CA, USA.ORCID 0000-0001-5308-615X
Zhaohui L ArterDepartment of Medicine, University of California Irvine School of Medicine, Orange, CA, USA.ORCID 0000-0001-7394-7156
Cathleen J ParkDepartment of Medicine, University of California Irvine School of Medicine, Orange, CA, USA.ORCID 0009-0004-7229-2222
Akshat SarkariDepartment of Medicine, University of California Irvine School of Medicine, Orange, CA, USA.
Sai-Hong Ignatius OuDepartment of Medicine, University of California Irvine School of Medicine, Orange, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trastuzumab deruxtecan, zongertinib and sevabertinib have been approved in the United States for the treatment of patients with advanced metastatic HER2 mutated non-small-cell lung cancer (NSCLC). Unfortunately, tumor progression is inevitable in many cases. In this case report, we share our experience with a patient with HER2 mutated NSCLC who responded to the combination of trastuzumab deruxtecan and zongertinib after progressing on each agent when given alone, highlighting the potential for such combinations.

Indexed as

combination therapyHER2 mutationmechanism of resistanceT-Dxdtrastuzumab deruxtecan

Identifiers

PMID42158839
PMCPMC13182726

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.